A phase II study of TAS-117 in patients with advanced solid tumors harboring germline -inactivating mutations.
Fiche publication
Date publication
août 2022
Journal
Future oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HERVIEU Alice
Tous les auteurs :
Rodón J, Funchain P, Laetsch TW, Arkenau HT, Hervieu A, Singer CF, Murciano-Goroff YR, Chawla SP, Anthony K, Yamamiya I, Liu M, Halim AB, Benhadji KA, Takahashi O, Delaloge S
Lien Pubmed
Résumé
PTEN acts as a potent tumor suppressor within the PI3K/AKT/mTOR pathway. Germline mutations in the gene are a hallmark of PTEN hamartoma tumor syndrome, which includes Cowden syndrome, where they appear to elevate lifetime risk of cancer. Targeted AKT directed therapy has been proposed as an effective approach in cancer patients having germline mutations. The mechanism of action, safety and dosing regimen for the novel allosteric AKT inhibitor TAS-117 have been explored in a phase I study in Japan in which activity was observed against certain tumor types. Here we describe the study protocol of an international, two-part Phase II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TAS-117 in patients with advanced solid tumors harboring germline -inactivating mutations.
Mots clés
Cowden syndrome, PTEN hamartoma tumor syndrome, PTEN inactivation, TAS-117, advanced solid tumor, clinical trial, germline PTEN mutation
Référence
Future Oncol. 2022 08 30;: